Stockscreener 앱 받기
0.3324
0.54%
0.0018
전일 마감가:
$0.3306
열려 있는:
$0.3325
하루 거래량:
48,821
Relative Volume:
0.09
시가총액:
$7.32M
수익:
$275.60K
순이익/손실:
$-8.33M
주가수익비율:
-0.7196
EPS:
-0.4619
순현금흐름:
$-5.40M
1주 성능:
-5.03%
1개월 성능:
-30.89%
6개월 성능:
-33.27%
1년 성능:
-54.47%
1일 변동 폭
$0.3275
$0.3326
1주일 범위
$0.325
$0.3599
52주 변동 폭
$0.305
$2.00
Nexalin Technology Inc Stock (NXL) Company Profile
명칭
Nexalin Technology Inc
전화
(832) 260-0222
주소
1776 YORKTOWN, HOUSTON
Compare NXL vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
0.3324 | 7.27M | 275.60K | -8.33M | -5.40M | -0.4619 |
ABT
Abbott Laboratories
|
116.25 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.75 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.85 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
50.45 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.54 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Nexalin Technology Inc 주식(NXL)의 최신 뉴스
Nexalin Announces Capital Raise and Flexible Equity Facility - TipRanks
Nexalin Technology Raises $750,000 in Registered Direct Offering - Minichart
Nexalin Technology Announces $0.75M Direct Offering and $15M Equity Purchase Facility With Alumni Capital - TradingView
Nexalin (NXL) EPS and Revenue: EPS Does Not Reach the Reported Estimate in the Available Record; The Share Price Sheds 2.06% in Latest TradingEPS Guidance Update - dars.gov.et
Nexalin Faces New Nasdaq Equity Deficiency, Delisting Risk - The Globe and Mail
Nexalin Technology Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nexalin Technology earnings missed, revenue fell short of estimates By Investing.com - Investing.com South Africa
Nexalin Technology earnings missed, revenue fell short of estimates - Investing.com
Nexalin Technology Inc. (NASDAQ: NXL) Share Price, NXL Stock News, NXL Share Price & Updates - Kalkine
Nexalin Technology, Inc. 2Q 2026: Revenue $12.16K, EPS ($0.11) — 10-Q Summary - TradingView
Nexalin Technology (NXL) flags going concern risk as losses mount and Nasdaq warns - Stock Titan
Nexalin Technology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Nexalin Technology | 8-K: Current report - Moomoo
Nexalin Technology Inc (NXL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nexalin Technology Inc (NXL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nexalin Technology Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Nexalin Expands and Extends Houston Headquarters Lease Commitment - The Globe and Mail
Nexalin Appeals Nasdaq Delisting Following Compliance Shortfalls - The Globe and Mail
Nexalin Technology Inc (NXL) Institutional Confidence - TradingKey
Nexalin Technology Received Notice of Delisting - TradingView
Nexalin Technology Inc (NXL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NXL|Nexalin Technology Inc|Price:0.353|Chg%:+0.014 - TradingKey
Nexalin Technology Inc (NXL) Cash Flow - TradingKey
Nexalin Technology Inc (NXL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NXL|Nexalin Technology Inc|Price:0.500|Chg%:+0.019 - TradingKey
Nexalin Technology Inc (NXL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nexalin Technology Inc (NXL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NXL|Nexalin Technology Inc|Price:0.481|Chg%:+0.013 - TradingKey
NXL Q1 2026 Earnings: EPS Misses Estimates as Company Advances Non-Invasive Neuromodulation PipelineNew Analyst Coverage - Vinanet
Nexalin Technology, Inc. Revenue Breakdown – NASDAQ:NXL - TradingView
NXL Q1 2026 Earnings: EPS Misses Estimates by 8.91% While Shares Edge HigherQuarterly Profit Report - Vinanet
NXL Q1 2026 Earnings: Loss Per Share Misses Estimates as Development Continues Without Revenue - Vinanet
Nexalin Technology (NXL) Registration filing Summary - Quartr
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life - True North Radio Network
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Miss Slightly Wider Than Anticipated; Stock Rises on No Revenue UpdateEarnings Per Share - Vinanet
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue Development StageFinal Results - Vinanet
Nexalin Technology (NXL) Surges Over 11% as Shares Test Key Resistance LevelATR Stop - dars.gov.et
NXL | Nexalin Technology, Inc. Common Executive Compensation - Quiver Quantitative
Nexalin Technology | ARS: Annual Report to Security Holders - Moomoo
Form DEF 14A Nexalin Technology Inc For: 10 July By Investing.com - Investing.com Nigeria
Nexalin Technology (NXL) plans new 7M-share incentive pool and reverse split authority - Stock Titan
Nexalin Technology, Inc. SEC Filing (Jul 10, 2026) - Stock Titan
Nexalin Technology (NXL) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Stage ContinuesFinal Results - DonanımHaber
Enterprise value to revenue forward of Nexalin Technology, Inc. – NASDAQ:NXL - TradingView
Price to book forward of Nexalin Technology, Inc. – NASDAQ:NXL - TradingView
Price to sales forward of Nexalin Technology, Inc. – NASDAQ:NXL - TradingView
Price to earnings forward of Nexalin Technology, Inc. – NASDAQ:NXL - TradingView
NXL Q1 2026 Earnings: EPS Misses Estimates, Stock Declines 5%Margin Compression Risk - dars.gov.et
Form PRE 14A Nexalin Technology Inc For: 29 June By Investing.com - Investing.com South Africa
Nexalin Technology (NXL) seeks shareholder votes for equity plan, reverse split - Stock Titan
NexaLine Technology Registers 1.2 Million Shares for Resale - Moomoo
Nexalin Technology Inc (NXL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.26%
0.20%
자본화:
|
볼륨(24시간):